The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009
...ill save children's lives. The primary mission of The Max Cure Fund is to raise $5 million to underwrite the establishment of a research laboratory at mskcc
in the Department of Pediatrics. The lab will be devoted to researching, treating and curing childhood cancers. The Max Cure Fund was established in...
Study shows drug combination improves outcome for advanced non-small cell lung cancer
...aintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," said Dr. Miller, a thoracic oncologist at mskcc
and one of the study's lead authors. "Knowing which patients will get the greatest benefit from this combination, based on the identification of bioma...
Surgery not necessary for most late-stage colorectal cancers
...ssary," said Philip Paty, a surgical oncologist at mskcc
and one of the study's lead authors. "If the colon... 233 metastatic colorectal cancer cases treated at mskcc
from 2000 to 2006. Their analysis showed that 217 ...otherapy treatments in the past decade, doctors at mskcc
and others within the oncology community started l...
Ontario Systems Signs Multi-Year Agreement with Memorial Sloan-Kettering Cancer Center
...management industries, today announces a multi-year contract with Memorial Sloan-Kettering Cancer Center (MSKCC), the nation's premier cancer center. mskcc
has purchased Ontario Systems' Revenue Savvy to manage the Center's revenue cycle using powerful new tools to follow up on third-party claims and mana...
New minimally invasive surgery option for patients with stomach cancer
...y's lead author Vivian E. Strong, MD, a surgeon at mskcc
who specializes in laparoscopic surgery for the tr...perience performing the laparoscopic procedure."
is one of the few National Cancer Institutedesigna... open and laparoscopic, are performed each year at mskcc
one of the highest volumes of surgery for this re...
Drug shows activity in men with advanced prostate cancer
..." said Dr. Sawyers, Chair of the Human Oncology and Pathogenesis Program at mskcc
and a Howard Hughes Medical Institute investigator.
Current treatments fo...oral MDV3100 a Phase 1/2 clinical trial, which was led by investigators at mskcc
and conducted through the Prostate Cancer Clinical Trials Consortium. The C...
NIH awards $15.9 million to CCNY and Memorial Sloan-Kettering to create partnership
... multidisciplinary, but unified approach to several objectives set forth by mskcc
"We are looking forward to partnering with CCNY to improve can...al practice and clinical observations are studied in the laboratory.
and CCNY will collaborate with diverse communities to help define and addre...
Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting
...with the goal of ultimately helping physicians to better tailor treatment to a patient's individual tumor."
Imaging experiments in mice conducted at mskcc
showed that this new particle platform, or "probe," can be molecularly customized to target surface receptors or other molecules that are expressed on...
Researchers learn how signaling molecule orchestrates breast cancer's spread
...tem to promote the spread of breast cancer," said the study's senior author, Joan Massagu, PhD, Chairman of the Cancer Biology and Genetics Program at mskcc
and a Howard Hughes Medical Institute investigator.
The researchers are now seeking to determine whether TGF-a and ANGPTL4 may also be active in ot...
Novel mechanism found that may boost impaired function of leukemia protein
...acute leukemia, said the studys first author, Xinyang Zhao, a member of Dr. Nimers laboratory.
Dr. Nimer has been researching the AML1-ETO protein at mskcc
since 1993. He and his colleagues first demonstrated in 1995 that AML1-ETO functions as a transcriptional repressor and dominantly inhibits AML1 funct...
AlphaVax Announces Promising Results in Melanoma Studies
...ancesca Avogadri, Ph.D., a Research Fellow in the Department of Medicine at mskcc
presented data at the American Association of Immunologists Annual Meeting ...in Seattle, Washington.
Results from pre-clinical studies conducted at mskcc
demonstrate the ability of AlphaVax's virus-like replicon vector particles ...
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
... Keating and colleagues at the University of Texas M.D. Anderson Cancer Center. Previous US Oncology Research Network, as well as a Mayo Clinic and mskcc
trials, evaluated the combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR); results suggested similar efficacy with less infe...
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
...ltiple vaccines against recurrent cancer for
six different types of cancer. mskcc
plans to initiate Phase I clinical
trials in each of these types of cancer ...Phase II
trials in these two cancer types. In addition to MabVax's efforts, mskcc
planning to conduct Phase II trials with the licensed vaccines in ovaria...
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
"As we predicted using the Norton-Simon mathematical model -- the basis
for the dose dense approach to therapy that was pioneered at mskcc
results demonstrate that a biweekly regimen of capecitabine appears to be
well-tolerated, at dosing levels that are higher than previously th...
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Patients in the study were randomized according to Memorial Sloan-
Kettering Cancer Center (MSKCC) risk criteria and prior anti-cancer
risk criteria are standard clinical criteria to determine
the prognosis of patients with RCC.
In addition to RCC, everolimus is presently being eval...
Biotec Pharmacon Announces Preliminary Results from the
Sloan-Kettering Clinical Study
...marrow testing. The preliminary data is
considered to be an improvement compared to what would be expected
if the monoclonal antibody was given alone. mskcc
has earlier shown
that the effectiveness of the antibody could be improved by the use
of intravenous injection of the recombinant cytokine GM-CSF,
NYU and MSKCC research provides model for understanding chemically induced cancer initiation
A team from the chemistry and biology departments of New York University, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), has uncovered a conformational switch--a change in shape in a carcinogen-damaged DNA site--in tumor suppressor genes altered by a known cancer-causing chem...
Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer
... Cancer Center on December 6, 2007.
Each investigator we are honoring is already a leader in his or her respective field, said Harold Varmus, M.D., mskcc
President. These scientists have made major contributions to the biological understanding of cancer, shedding light on what causes cancer and offering...
Sickle cell disease corrected in human models using stem cell-based gene therapy
... not available to most patients due to the difficulty in finding a compatible donor," explained Michel Sadelain, MD, PhD, of the Immunology Program at mskcc
and the study's senior author. "By using gene transfer, there is always a donor match because the patient's own stem cells are used to treat the disea...
MSKCC researchers uncover structure of key protein complex in cells
...for cancer and other conditions in which SUMO is involved."
The study also casts light on a poorly understood aspect of cellular communication. The mskcc
researchers believe the protein complex they have observed is assembled at nuclear pore complexes, portals that connect the nucleus with the cytoplasm...